pancreatic cancer
Conditions
Interventions
Combined chemotherapy group:S-1, PD-1 mAb and anti-angiogenesis drugs
Sponsors
Nanjing Drum Tower Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: a. Aged 18 - 75 years, ECOG score = 3 months. b. Histological or cytologically confirmed patients with liver metastases from pancreatic cancer. c. Imaging suggests measurable lesions in the liver. d. The first-line chemotherapy failed, and the first-line chemotherapy did not use fluorouracil drugs, PD-1 mAb and anti-angiogenesis drugs. e. Patients need to meet the following hematological indicators e1. Neutrophil count >= 1.5 x 10 ^ 9 e2. Hemoglobin >= 10g / dL e3. Platelet count >= 100 x 10 ^ 9 f. Patients need to meet the following biochemical indicators f1. Total bilirubin = 60ml / min g. Patients of childbearing age need to take appropriate protective measures (contraceptives or other methods of birth control) before enrollment and during the trial. h. Informed Consent signed. i. Ability to follow research protocols and follow-up procedures.
Exclusion criteria
Exclusion criteria: a. Patients who have received anti-tumor treatment above the second line. b. First-line treatment used perfluorouracil drugs, PD-1 monoclonal antibodies or anti-angiogenic drugs. c. Patients with a history of other tumors, except for cervical carcinoma in situ, treated squamous cell carcinoma, bladder epithelial tumors (Ta and TIS) or other malignant tumors that have been treated radically (at least 5 years before enrollment) . d. Patients with an active bacterial or fungal infection (> = Level 2 of NCI-CTC, 3rd Edition). e. Patients with HIV, HCV, HBV infection, uncontrollable coronary artery disease or asthma, uncontrollable cerebrovascular disease or other diseases that researchers consider unenrollable. f. Patients with autoimmune diseases, immunodeficiency or treated with immunosuppressive drugs. g. Pregnant and lactating patients. Patients of childbearing age must have a negative pregnancy test within 7 days before enrollment. h. Drug abuse, clinical or psychological or social factors that affect informed consent or research implementation. i. Patients who may be allergic to PD-1 monoclonal antibody immunotherapy drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;ORR;DCR; | — |
Countries
China
Contacts
Public ContactJuan Du
Nanjing Drum Tower Hospital
Outcome results
None listed